Matarin Capital Management’s Charles River Laboratories CRL Stock Holding History

Matarin Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-9,765	Closed	-$785K	–	233
2015 Q4	$785K	Sell	9,765 -26,472	-73%	-$1.91M	0.12%	174
2015 Q3	$2.3M	Buy	36,237 +13,097	+57%	+$941K	0.47%	80
2015 Q2	$1.63M	Sell	23,140 -733	-3%	-$54.2K	0.47%	96
2015 Q1	$1.89M	Buy	+23,873	New	+$1.76M	0.58%	84
2014 Q4	–	Sell	-4,015	Closed	-$240K	–	154
2014 Q3	$240K	Sell	4,015 -1,380	-26%	-$79K	0.11%	162
2014 Q2	$289K	Buy	+5,395	New	+$296K	0.13%	153

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Matarin Capital Management's CRL Position: Q1 2016 in Review

Matarin Capital Management sold out of Charles River Laboratories (CRL) in Q1 2016, closing a stake of 9,765 shares — an estimated $785K sold.

Matarin Capital Management first reported a position in CRL in Q2 2014 and held it in 6 quarters. The position peaked at $2.3M in Q3 2015. 264 funds tracked by Wall St. Rank hold CRL as of Q1 2016.

Matarin Capital Management reported no remaining Charles River Laboratories position as of Q1 2016 after selling out during the quarter.
Matarin Capital Management sold 9,765 Charles River Laboratories shares in Q1 2016, an estimated $785K.
Matarin Capital Management first reported a position in Charles River Laboratories in Q2 2014 and held it in 6 quarters.
Matarin Capital Management's Charles River Laboratories position peaked at $2.3M in Q3 2015.
264 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2016.

Based on Matarin Capital Management's 13F filing for Q1 2016, filed 10 May 2016.